company background image
FZRQ logo

Immune Pharmaceuticals DB:FZRQ Stock Report

Last Price

€0.0031

Market Cap

€369.5k

7D

-68.7%

1Y

3.3%

Updated

03 Apr, 2020

Data

Company Financials

Immune Pharmaceuticals, Inc.

DB:FZRQ Stock Report

Market Cap: €369.5k

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

FZRQ Stock Overview

Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases.

FZRQ fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Immune Pharmaceuticals, Inc. Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Immune Pharmaceuticals
Historical stock prices
Current Share PriceUS$0.0031
52 Week HighUS$0
52 Week LowUS$0
Beta0
1 Month Change1,450.00%
3 Month Change210.00%
1 Year Change3.33%
3 Year Change-99.88%
5 Year Change-99.99%
Change since IPOn/a

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

FZRQDE BiotechsDE Market
7D-68.7%2.3%1.2%
1Y3.3%31.8%5.5%

Return vs Industry: FZRQ exceeded the German Biotechs industry which returned -10.6% over the past year.

Return vs Market: FZRQ exceeded the German Market which returned -20.4% over the past year.

Price Volatility

Is FZRQ's price volatile compared to industry and market?
FZRQ volatility
FZRQ Average Weekly Movementn/a
Biotechs Industry Average Movement5.8%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.0%
10% least volatile stocks in DE Market2.5%

Stable Share Price: FZRQ's share price has been volatile over the past 3 months.

About the Company

FoundedEmployeesCEOWebsite
2010n/aGary Rabinhttps://www.immunepharma.com

Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company’s lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis.

Immune Pharmaceuticals, Inc. Fundamentals Summary

How do Immune Pharmaceuticals's earnings and revenue compare to its market cap?
FZRQ fundamental statistics
Market cap€369.55k
Earnings (TTM)-€31.61m
Revenue (TTM)n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
FZRQ income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$34.39m
Earnings-US$34.39m

Last Reported Earnings

Sep 30, 2018

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did FZRQ perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.